{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:00:26Z","timestamp":1785891626186,"version":"3.56.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R03 CA219718"],"award-info":[{"award-number":["R03 CA219718"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA222802"],"award-info":[{"award-number":["R01 CA222802"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Tumors are heterogeneous in nature, composed of different cell populations with various mutations and\/or phenotypes. Using a single drug to encounter cancer progression is generally ineffective. To improve the treatment outcome, multiple drugs of distinctive mechanisms but complementary anticancer activities (combination therapy) are often used to enhance antitumor efficacy and minimize the risk of acquiring drug resistance. We report here the synergistic effects of salinomycin (a polyether antibiotic) and dasatinib (a Src kinase inhibitor).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Functionally, both drugs induce cell cycle arrest, intracellular reactive oxygen species (iROS) production, and apoptosis. We rationalized that an overlapping of the drug activities should offer an enhanced anticancer effect, either through vertical inhibition of the Src-STAT3 axis or horizontal suppression of multiple pathways. We determined the toxicity induced by the drug combination and studied the kinetics of iROS production by fluorescence imaging and flow cytometry. Using genomic and proteomic techniques, including RNA-sequencing (RNA-seq), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and Western Blot, we subsequently identified the responsible pathways that contributed to the synergistic effects of the drug combination.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Compared to either drug alone, the drug combination showed enhanced potency against MDA-MB-468, MDA-MB-231, and MCF-7 human breast cancer (BC) cell lines and tumor spheroids. The drug combination induces both iROS generation and apoptosis in a time-dependent manner, following a 2-step kinetic profile. RNA-seq data revealed that the drug combination exhibited synergism through horizontal suppression of multiple pathways, possibly through a promotion of cell cycle arrest at the G1\/S phase via the estrogen-mediated S-phase entry pathway, and partially via the BRCA1 and DNA damage response pathway.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Transcriptomic analyses revealed for the first time, that the estrogen-mediated S-phase entry pathway partially contributed to the synergistic effect of the drug combination. More importantly, our studies led to the discoveries of new potential therapeutic targets, such as E2F2, as well as a novel drug-induced targeting of estrogen receptor \u03b2 (ESR2) approach for triple-negative breast cancer treatment, currently lacking of targeted therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07134-3","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T09:02:46Z","timestamp":1594890166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor \u03b2"],"prefix":"10.1186","volume":"20","author":[{"given":"Vanessa","family":"Bellat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Verch\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Ashe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7673-659X","authenticated-orcid":false,"given":"Benedict","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"issue":"1","key":"7134_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Ca-Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"Ca-Cancer J Clin"},{"issue":"7","key":"7134_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kummel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(14)70160-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7134_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13\u201321. https:\/\/doi.org\/10.1200\/JCO.2014.57.0572.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7134_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.breast.2012.07.014","volume":"22","author":"WX Qi","year":"2013","unstructured":"Qi WX, Tang LN, He AN, Shen Z, Yao Y. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials. Breast. 2013;22(3):314\u20139. https:\/\/doi.org\/10.1016\/j.breast.2012.07.014.","journal-title":"Breast"},{"key":"7134_CR5","doi-asserted-by":"publisher","unstructured":"Nunes T, Hamdan D, Leboeuf C, El Bouchtaoui M, Gapihan G, Nguyen TT, Meles S, Angeli E, Ratajczak P, Lu H, Di Benedetto M, Bousquet G, Janin A. Targeting Cancer stem cells to overcome Chemoresistance. Int J Mol Sci. 2018;19(12). https:\/\/doi.org\/10.3390\/ijms19124036.","DOI":"10.3390\/ijms19124036"},{"issue":"1","key":"7134_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/pr.58.3.10","volume":"59","author":"TC Chou","year":"2007","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug-combination studies (vol 58, pg 621, 2006). Pharmacol Rev. 2007;59(1):124. https:\/\/doi.org\/10.1124\/pr.58.3.10.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"7134_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","volume":"138","author":"PB Gupta","year":"2009","unstructured":"Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645\u201359. https:\/\/doi.org\/10.1016\/j.cell.2009.06.034.","journal-title":"Cell"},{"issue":"23","key":"7134_CR8","doi-asserted-by":"publisher","first-page":"7146","DOI":"10.1016\/j.bmcl.2012.09.068","volume":"22","author":"A Huczynski","year":"2012","unstructured":"Huczynski A, Janczak J, Antoszczak M, Wietrzyk J, Maj E, Brzezinski B. Antiproliferative activity of salinomycin and its derivatives. Bioorg Med Chem Lett. 2012;22(23):7146\u201350. https:\/\/doi.org\/10.1016\/j.bmcl.2012.09.068.","journal-title":"Bioorg Med Chem Lett"},{"issue":"23","key":"7134_CR9","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1016\/j.bmcl.2012.09.046","volume":"22","author":"A Huczynski","year":"2012","unstructured":"Huczynski A. Polyether ionophores-promising bioactive molecules for cancer therapy. Bioorg Med Chem Lett. 2012;22(23):7002\u201310. https:\/\/doi.org\/10.1016\/j.bmcl.2012.09.046.","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"7134_CR10","doi-asserted-by":"publisher","first-page":"e44132","DOI":"10.1371\/journal.pone.0044132","volume":"7","author":"B Verdoodt","year":"2012","unstructured":"Verdoodt B, Vogt M, Schmitz I, Liffers ST, Tannapfel A, Mirmohammadsadegh A. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One. 2012;7(9):e44132. https:\/\/doi.org\/10.1371\/journal.pone.0044132.","journal-title":"PLoS One"},{"issue":"8","key":"7134_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","volume":"12","author":"N Takebe","year":"2015","unstructured":"Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445\u201364. https:\/\/doi.org\/10.1038\/nrclinonc.2015.61.","journal-title":"Nat Rev Clin Oncol"},{"key":"7134_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s11658-018-0078-0","volume":"23","author":"M Galoczova","year":"2018","unstructured":"Galoczova M, Coates P, Vojtesek B. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. 2018;23:12. https:\/\/doi.org\/10.1186\/s11658-018-0078-0.","journal-title":"Cell Mol Biol Lett"},{"key":"7134_CR13","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1038\/cddis.2013.223","volume":"4","author":"KH Koo","year":"2013","unstructured":"Koo KH, Kim H, Bae YK, Kim K, Park BK, Lee CH, Kim YN. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Dis. 2013;4:e693. https:\/\/doi.org\/10.1038\/cddis.2013.223.","journal-title":"Cell Death Dis"},{"key":"7134_CR14","doi-asserted-by":"publisher","first-page":"e1039","DOI":"10.1038\/cddis.2013.515","volume":"5","author":"J Mao","year":"2014","unstructured":"Mao J, Fan S, Ma W, Fan P, Wang B, Zhang J, Wang H, Tang B, Zhang Q, Yu X, Wang L, Song B, Li L. Roles of Wnt\/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis. 2014;5:e1039. https:\/\/doi.org\/10.1038\/cddis.2013.515.","journal-title":"Cell Death Dis"},{"issue":"1","key":"7134_CR15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1186\/s12885-016-2879-8","volume":"16","author":"J Klose","year":"2016","unstructured":"Klose J, Eissele J, Volz C, Schmitt S, Ritter A, Ying S, Schmidt T, Heger U, Schneider M, Ulrich A. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt\/beta-catenin signaling in CD133(+) human colorectal cancer cells. BMC Cancer. 2016;16(1):896. https:\/\/doi.org\/10.1186\/s12885-016-2879-8.","journal-title":"BMC Cancer"},{"issue":"2","key":"7134_CR16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3892\/or.2015.4434","volume":"35","author":"YZ Fu","year":"2016","unstructured":"Fu YZ, Yan YY, He M, Xiao QH, Yao WF, Zhao L, Wu HZ, Yu ZJ, Zhou MY, Lv MT, Zhang SS, Chen JJ, Wei MJ. Salinomycin induces selective cytotoxicity to MCF-7 mammosphere cells through targeting the hedgehog signaling pathway. Oncology Rep. 2016;35(2):912\u201322. https:\/\/doi.org\/10.3892\/or.2015.4434.","journal-title":"Oncology Rep"},{"issue":"11","key":"7134_CR17","doi-asserted-by":"publisher","first-page":"e0141919","DOI":"10.1371\/journal.pone.0141919","volume":"10","author":"H An","year":"2015","unstructured":"An H, Kim JY, Oh E, Lee N, Cho Y, Seo JH. Salinomycin promotes Anoikis and decreases the CD44+\/CD24- stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells. PLoS One. 2015;10(11):e0141919. https:\/\/doi.org\/10.1371\/journal.pone.0141919.","journal-title":"PLoS One"},{"issue":"2","key":"7134_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.21873\/anticanres.11336","volume":"37","author":"SS Chung","year":"2017","unstructured":"Chung SS, Adekoya D, Enenmoh I, Clarke O, Wang P, Sarkyssian M, Wu Y, Vadgama JV. Salinomycin abolished STAT3 and STAT1 interactions and reduced telomerase activity in colorectal Cancer cells. Anticancer Res. 2017;37(2):445\u201353. https:\/\/doi.org\/10.21873\/anticanres.11336.","journal-title":"Anticancer Res"},{"issue":"3","key":"7134_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1476-5381.2010.01089.x","volume":"162","author":"JH Kim","year":"2011","unstructured":"Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011;162(3):773\u201384. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01089.x.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"7134_CR20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s10637-011-9685-6","volume":"30","author":"WK Kim","year":"2012","unstructured":"Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S. Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Investig New Drugs. 2012;30(4):1311\u20138. https:\/\/doi.org\/10.1007\/s10637-011-9685-6.","journal-title":"Investig New Drugs"},{"issue":"1","key":"7134_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bbrc.2011.12.141","volume":"418","author":"JH Kim","year":"2012","unstructured":"Kim JH, Yoo HI, Kang HS, Ro J, Yoon S. Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem Biophys Res Comm. 2012;418(1):98\u2013103. https:\/\/doi.org\/10.1016\/j.bbrc.2011.12.141.","journal-title":"Biochem Biophys Res Comm"},{"issue":"6","key":"7134_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1517\/13543784.2013.793308","volume":"22","author":"KS Scher","year":"2013","unstructured":"Scher KS, Somlo G. Dasatinib : a novel therapy for breast cancer? Expert Opin Investig Drugs. 2013;22(6):795\u2013801. https:\/\/doi.org\/10.1517\/13543784.2013.793308.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"7134_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.canlet.2009.03.035","volume":"283","author":"J Nautiyal","year":"2009","unstructured":"Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 2009;283(2):143\u201351. https:\/\/doi.org\/10.1016\/j.canlet.2009.03.035.","journal-title":"Cancer Lett"},{"issue":"14","key":"7134_CR24","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-09-1834","volume":"16","author":"EL Mayer","year":"2010","unstructured":"Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010;16(14):3526\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1834.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7134_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14728222.12.6.757","volume":"12","author":"S Hiscox","year":"2008","unstructured":"Hiscox S, Nicholson RI. Src inhibitors in breast cancer therapy. Expert Opin Ther Targets. 2008;12(6):757\u201367. https:\/\/doi.org\/10.1517\/14728222.12.6.757.","journal-title":"Expert Opin Ther Targets"},{"key":"7134_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/1471-2407-10-568","volume":"10","author":"J Kurebayashi","year":"2010","unstructured":"Kurebayashi J, Kanomata N, Moriya T, Kozuka Y, Watanabe M, Sonoo H. Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer. 2010;10:568. https:\/\/doi.org\/10.1186\/1471-2407-10-568.","journal-title":"BMC Cancer"},{"key":"7134_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3389\/fphar.2018.01285","volume":"9","author":"YT Tzeng","year":"2018","unstructured":"Tzeng YT, Liu PF, Li JY, Liu LF, Kuo SY, Hsieh CW, Lee CH, Wu CH, Hsiao M, Chang HT, Shu CW. Kinome-wide siRNA screening identifies Src-enhanced resistance of chemotherapeutic drugs in triple-negative breast Cancer cells. Front Pharmacol. 2018;9:1285. https:\/\/doi.org\/10.3389\/fphar.2018.01285.","journal-title":"Front Pharmacol"},{"issue":"8","key":"7134_CR28","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/1087057106292763","volume":"11","author":"A Ivascu","year":"2006","unstructured":"Ivascu A, Kubbies M. Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen. 2006;11(8):922\u201332. https:\/\/doi.org\/10.1177\/1087057106292763.","journal-title":"J Biomol Screen"},{"issue":"1","key":"7134_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics"},{"issue":"1","key":"7134_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nbt.2450","volume":"31","author":"C Trapnell","year":"2013","unstructured":"Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nature Biotech. 2013;31(1):46. https:\/\/doi.org\/10.1038\/nbt.2450.","journal-title":"Nature Biotech"},{"key":"7134_CR31","doi-asserted-by":"publisher","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15 (12). Doi: ARTN 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","DOI":"10.1186\/s13059-014-0550-8"},{"issue":"6","key":"7134_CR32","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1186\/s13059-014-0550-8","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101\u20138. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Nat Protoc"},{"issue":"3","key":"7134_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u201381. https:\/\/doi.org\/10.1124\/pr.58.3.10.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"7134_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","volume":"105","author":"RS Finn","year":"2007","unstructured":"Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\"triple-negative\" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105(3):319\u201326. https:\/\/doi.org\/10.1007\/s10549-006-9463-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"7134_CR35","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1158\/1535-7163.MCT-09-0243","volume":"8","author":"PG Tardi","year":"2009","unstructured":"Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther. 2009;8(8):2266\u201375. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0243.","journal-title":"Mol Cancer Ther"},{"key":"7134_CR36","doi-asserted-by":"publisher","first-page":"832059","DOI":"10.1155\/2012\/832059","volume":"2012","author":"E Tsakalozou","year":"2012","unstructured":"Tsakalozou E, Eckman AM, Bae Y. Combination effects of docetaxel and doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int. 2012;2012:832059. https:\/\/doi.org\/10.1155\/2012\/832059.","journal-title":"Biochem Res Int"},{"key":"7134_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jconrel.2014.09.024","volume":"196","author":"NA Fonseca","year":"2014","unstructured":"Fonseca NA, Gomes-da-Silva LC, Moura V, Simoes S, Moreira JN. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive\/antagonistic drug interaction of non-encapsulated combination. J Control Release. 2014;196:122\u201331. https:\/\/doi.org\/10.1016\/j.jconrel.2014.09.024.","journal-title":"J Control Release"},{"issue":"9","key":"7134_CR38","doi-asserted-by":"publisher","first-page":"e108283","DOI":"10.1371\/journal.pone.0108283","volume":"9","author":"AL Howes","year":"2014","unstructured":"Howes AL, Richardson RD, Finlay D, Vuori K. 3-dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems. PLoS One. 2014;9(9):e108283. https:\/\/doi.org\/10.1371\/journal.pone.0108283.","journal-title":"PLoS One"},{"issue":"2","key":"7134_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2012.04.045","volume":"164","author":"G Mehta","year":"2012","unstructured":"Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release. 2012;164(2):192\u2013204. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.045.","journal-title":"J Control Release"},{"key":"7134_CR40","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1039\/b902415h","volume":"19","author":"NS Bryce","year":"2009","unstructured":"Bryce NS, Zhang JZ, Whan RM, Yamamoto N, Hambley TW. Accumulation of an anthraquinone and its platinum complexes in cancer cell spheroids: the effect of charge on drug distribution in solid tumour models. Chem Commun (Camb). 2009;19:2673\u20135. https:\/\/doi.org\/10.1039\/b902415h.","journal-title":"Chem Commun (Camb)"},{"key":"7134_CR41","doi-asserted-by":"publisher","unstructured":"Bellat V, Ting R, Southard TL, Vahdat L, Molina H, Fernandez J, Aras O, Stokol T, Law B. Functional peptide Nanofibers with unique tumor targeting and enzyme-induced local retention properties. Adv Funct Mater. 2018;28(44). https:\/\/doi.org\/10.1002\/adfm.201803969.","DOI":"10.1002\/adfm.201803969"},{"issue":"6","key":"7134_CR42","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.3892\/or.2017.5615","volume":"37","author":"SN Yu","year":"2017","unstructured":"Yu SN, Kim SH, Kim KY, Ji JH, Seo YK, Yu HS, Ahn SC. Salinomycin induces endoplasmic reticulum stressmediated autophagy and apoptosis through generation of reactive oxygen species in human glioma U87MG cells. Oncol Rep. 2017;37(6):3321\u20138. https:\/\/doi.org\/10.3892\/or.2017.5615.","journal-title":"Oncol Rep"},{"issue":"4","key":"7134_CR43","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.21873\/anticanres.11507","volume":"37","author":"KY Kim","year":"2017","unstructured":"Kim KY, Park KI, Kim SH, Yu SN, Lee D, Kim YW, Noh KT, Ma JY, Seo YK, Ahn SC. Salinomycin induces reactive oxygen species and apoptosis in aggressive breast Cancer cells as mediated with regulation of autophagy. Anticancer Res. 2017;37(4):1747\u201358. https:\/\/doi.org\/10.21873\/anticanres.11507.","journal-title":"Anticancer Res"},{"key":"7134_CR44","doi-asserted-by":"publisher","unstructured":"Kim KY, Park KI, Kim SH, Yu SN, Park SG, Kim YW, Seo YK, Ma JY, Ahn SC. Inhibition of autophagy promotes Salinomycin-induced apoptosis via reactive oxygen species-mediated PI3K\/AKT\/mTOR and ERK\/p38 MAPK-dependent signaling in human prostate Cancer cells. Int J Mol Sci. 2017;18(5). https:\/\/doi.org\/10.3390\/ijms18051088.","DOI":"10.3390\/ijms18051088"},{"issue":"8","key":"7134_CR45","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1248\/cpb.c17-00261","volume":"65","author":"Y Wu","year":"2017","unstructured":"Wu Y, Zhang D, Wu B, Quan Y, Liu D, Li Y, Zhang X. Synergistic activity of an antimetabolite drug and tyrosine kinase inhibitors against breast Cancer cells. Chem Pharm Bull (Tokyo). 2017;65(8):768\u201375. https:\/\/doi.org\/10.1248\/cpb.c17-00261.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"32","key":"7134_CR46","doi-asserted-by":"publisher","first-page":"13253","DOI":"10.1073\/pnas.1110431108","volume":"108","author":"D Lu","year":"2011","unstructured":"Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108(32):13253\u20137. https:\/\/doi.org\/10.1073\/pnas.1110431108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7134_CR47","unstructured":"Zhou S, Wang F, Zhang Y, Johnson MR, Qian S, Wu M, Wu E. Salinomycin suppresses PDGFRbeta, MYC, and notch signaling in human Medulloblastoma. Aust J Pharmacol Ther. 2014;2(3):1020. Pmcid: PMC4251667.."},{"issue":"4","key":"7134_CR48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s11064-016-2132-5","volume":"42","author":"SJ Zhao","year":"2017","unstructured":"Zhao SJ, Wang XJ, Wu QJ, Liu C, Li DW, Fu XT, Zhang HF, Shao LR, Sun JY, Sun BL, Zhai J, Fan CD. Induction of G1 cell cycle arrest in human Glioma cells by Salinomycin through triggering ROS-mediated DNA damage in vitro and in vivo. Neurochem Res. 2017;42(4):997\u20131005. https:\/\/doi.org\/10.1007\/s11064-016-2132-5.","journal-title":"Neurochem Res"},{"key":"7134_CR49","doi-asserted-by":"publisher","unstructured":"Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Borresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM. TP53 status as a determinant of pro- versus anti-tumorigenic effects of estrogen receptor-beta in breast Cancer. J Natl Cancer Inst. 2019. https:\/\/doi.org\/10.1093\/jnci\/djz051.","DOI":"10.1093\/jnci\/djz051"},{"issue":"42","key":"7134_CR50","doi-asserted-by":"publisher","first-page":"44675","DOI":"10.18632\/oncotarget.5971","volume":"6","author":"HW Lue","year":"2015","unstructured":"Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget. 2015;6(42):44675\u201387. https:\/\/doi.org\/10.18632\/oncotarget.5971.","journal-title":"Oncotarget"},{"issue":"24","key":"7134_CR51","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.7150\/jca.25138","volume":"9","author":"W Chien","year":"2018","unstructured":"Chien W, Sudo M, Ding LW, Sun QY, Wuensche P, Lee KL, Hattori N, Garg M, Xu L, Zheng Y, Gery S, Wongphayak S, Yang H, Baloglu E, Shacham S, Kauffman M, Mori S, Koeffler HP. Functional genome-wide screening identifies targets and pathways sensitizing pancreatic Cancer cells to Dasatinib. J Cancer. 2018;9(24):4762\u201373. https:\/\/doi.org\/10.7150\/jca.25138.","journal-title":"J Cancer"},{"issue":"2","key":"7134_CR52","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/1541-7786.MCR-17-0468","volume":"16","author":"EM Cousins","year":"2018","unstructured":"Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, Major MB. Competitive kinase enrichment proteomics reveals that Abemaciclib inhibits GSK3beta and Activates WNT signaling. Mol Cancer Res: MCR. 2018;16(2):333\u201344. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0468.","journal-title":"Mol Cancer Res: MCR"},{"issue":"6","key":"7134_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00210-016-1225-7","volume":"389","author":"AM Niwa","year":"2016","unstructured":"Niwa AM, Marques LA, Semprebon SC, Sartori D, Ribeiro LR, Mantovani MS. Salinomycin efficiency assessment in non-tumor (HB4a) and tumor (MCF-7) human breast cells. Naunyn Schmiedeberg's Arch Pharmacol. 2016;389(6):557\u201371. https:\/\/doi.org\/10.1007\/s00210-016-1225-7.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"24","key":"7134_CR54","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1038\/sj.emboj.7600481","volume":"23","author":"C Attwooll","year":"2004","unstructured":"Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004;23(24):4709\u201316. https:\/\/doi.org\/10.1038\/sj.emboj.7600481.","journal-title":"EMBO J"},{"issue":"11","key":"7134_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrc2696","volume":"9","author":"HZ Chen","year":"2009","unstructured":"Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9(11):785\u201397. https:\/\/doi.org\/10.1038\/nrc2696.","journal-title":"Nat Rev Cancer"},{"key":"7134_CR56","doi-asserted-by":"publisher","unstructured":"Thwaites MJ, Cecchini MJ, Passos DT, Welch I, Dick FA. Interchangeable roles for E2F transcriptional repression by the retinoblastoma protein and p27KIP1-Cyclin-dependent kinase regulation in cell cycle control and tumor suppression. Mol Cell Biol. 2017;37(2). https:\/\/doi.org\/10.1128\/MCB.00561-16.","DOI":"10.1128\/MCB.00561-16"},{"issue":"74","key":"7134_CR57","doi-asserted-by":"publisher","first-page":"33912","DOI":"10.18632\/oncotarget.26089","volume":"9","author":"D Austin","year":"2018","unstructured":"Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018;9(74):33912\u201330. https:\/\/doi.org\/10.18632\/oncotarget.26089.","journal-title":"Oncotarget"},{"issue":"5","key":"7134_CR58","doi-asserted-by":"publisher","first-page":"R74","DOI":"10.1186\/bcr2139","volume":"10","author":"F Novelli","year":"2008","unstructured":"Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nistico C, Fabi A, Buglioni S, Natali PG, Mottolese M. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 2008;10(5):R74. https:\/\/doi.org\/10.1186\/bcr2139.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"7134_CR59","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1210\/endo.142.9.8395","volume":"142","author":"G Lazennec","year":"2001","unstructured":"Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001;142(9):4120\u201330. https:\/\/doi.org\/10.1210\/endo.142.9.8395.","journal-title":"Endocrinology"},{"issue":"1","key":"7134_CR60","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1186\/s12885-016-2973-y","volume":"16","author":"S Schuler-Toprak","year":"2016","unstructured":"Schuler-Toprak S, Haring J, Inwald EC, Moehle C, Ortmann O, Treeck O. Agonists and knockdown of estrogen receptor beta differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer. 2016;16(1):951. https:\/\/doi.org\/10.1186\/s12885-016-2973-y.","journal-title":"BMC Cancer"},{"issue":"12","key":"7134_CR61","doi-asserted-by":"publisher","first-page":"13599","DOI":"10.18632\/oncotarget.7300","volume":"7","author":"I Bado","year":"2016","unstructured":"Bado I, Nikolos F, Rajapaksa G, Gustafsson JA, Thomas C. ERbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Oncotarget. 2016;7(12):13599\u2013611. https:\/\/doi.org\/10.18632\/oncotarget.7300.","journal-title":"Oncotarget"},{"key":"7134_CR62","doi-asserted-by":"publisher","first-page":"925703","DOI":"10.1155\/2015\/925703","volume":"2015","author":"N Hamilton","year":"2015","unstructured":"Hamilton N, Marquez-Garban D, Mah V, Fernando G, Elshimali Y, Garban H, Elashoff D, Vadgama J, Goodglick L, Pietras R. Biologic roles of estrogen receptor-beta and insulin-like growth factor-2 in triple-negative breast cancer. Biomed Res Int. 2015;2015:925703. https:\/\/doi.org\/10.1155\/2015\/925703.","journal-title":"Biomed Res Int"},{"issue":"26","key":"7134_CR63","doi-asserted-by":"publisher","first-page":"15197","DOI":"10.1073\/pnas.211556298","volume":"98","author":"EV Jensen","year":"2001","unstructured":"Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A. 2001;98(26):15197\u2013202. https:\/\/doi.org\/10.1073\/pnas.211556298.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"7134_CR64","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-04-1114","volume":"10","author":"TA Hopp","year":"2004","unstructured":"Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004;10(22):7490\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1114.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"7134_CR65","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-04-0389","volume":"10","author":"M Esslimani-Sahla","year":"2004","unstructured":"Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res. 2004;10(17):5769\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0389.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7134_CR66","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/s41598-017-01314-1","volume":"7","author":"J Espinal-Enriquez","year":"2017","unstructured":"Espinal-Enriquez J, Fresno C, Anda-Jauregui G, Hernandez-Lemus E. RNA-Seq based genome-wide analysis reveals loss of inter-chromosomal regulation in breast cancer. Sci Rep. 2017;7(1):1760. https:\/\/doi.org\/10.1038\/s41598-017-01314-1.","journal-title":"Sci Rep"},{"issue":"2","key":"7134_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5483\/bmbrep.2013.46.2.202","volume":"46","author":"SY Shin","year":"2013","unstructured":"Shin SY, Kim CG, Lee YH. Egr-1 regulates the transcription of the BRCA1 gene by etoposide. BMB Rep. 2013;46(2):92\u20136. https:\/\/doi.org\/10.5483\/bmbrep.2013.46.2.202.","journal-title":"BMB Rep"},{"issue":"1","key":"7134_CR68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2045-3701-2-6","volume":"2","author":"B Wang","year":"2012","unstructured":"Wang B. BRCA1 tumor suppressor network: focusing on its tail. Cell Biosci. 2012;2(1):6. https:\/\/doi.org\/10.1186\/2045-3701-2-6.","journal-title":"Cell Biosci"},{"issue":"4","key":"7134_CR69","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/ng1296-430","volume":"14","author":"LC Wu","year":"1996","unstructured":"Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet. 1996;14(4):430\u201340. https:\/\/doi.org\/10.1038\/ng1296-430.","journal-title":"Nat Genet"},{"issue":"8","key":"7134_CR70","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1021\/jacs.8b12872","volume":"141","author":"FF Wang","year":"2019","unstructured":"Wang FF, Zhou S, Qi D, Xiang SH, Wong ET, Wang XJ, Fonkem E, Hsieh TC, Yang JH, Kirmani B, Shabb JB, Wu JM, Wu M, Huang JSH, Yu WH, Wu EX. Nucleolin is a functional binding protein for Salinomycin in neuroblastoma stem cells. J Amer Chem Soc. 2019;141(8):3613\u201322. https:\/\/doi.org\/10.1021\/jacs.8b12872.","journal-title":"J Amer Chem Soc"},{"issue":"1","key":"7134_CR71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/14789450.2017.1256776","volume":"14","author":"M Guerin","year":"2017","unstructured":"Guerin M, Goncalves A, Toiron Y, Baudelet E, Audebert S, Boyer JB, Borg JP, Camoin L. How may targeted proteomics complement genomic data in breast cancer? Expert Rev Proteomic. 2017;14(1):43\u201354. https:\/\/doi.org\/10.1080\/14789450.2017.1256776.","journal-title":"Expert Rev Proteomic"},{"issue":"7","key":"7134_CR72","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1470-2045(16)00174-1","volume":"17","author":"TMA Abdel-Fatah","year":"2016","unstructured":"Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncol. 2016;17(7):1004\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(16)00174-1.","journal-title":"Lancet Oncol"},{"issue":"3","key":"7134_CR73","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10549-016-4011-9","volume":"160","author":"FX Cheng","year":"2016","unstructured":"Cheng FX, Zhao JF, Hanker AB, Brewer MR, Arteaga CL, Zhao ZM. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and hippo pathways altered by PIK3CA (H1047R) in HER2\/ER-positive breast cancer. Breast Cancer Res Tr. 2016;160(3):457\u201374. https:\/\/doi.org\/10.1007\/s10549-016-4011-9.","journal-title":"Breast Cancer Res Tr"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07134-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:22:23Z","timestamp":1626391343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7134"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07134-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"27 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"661"}}